Emerging drugs for eosinophilic esophagitis

Expert Opinion on Emerging Drugs

Volumn 18, Issue 3, 2013, Pages 353-364

  Kern, Emily ^a   Hirano, Ikuo ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

6 MP; AZA; Ciclesonide; CRTH2 antagonist; Dysphagia; Endoscopy; EoE; Eosinophilic esophagitis; Eotaxin 3; Esophagitis; FP; Gastroesophageal reflux disease; IL 13; IL 5; Infliximab; Leukotriene antagonist; Mepolizumab; OC000459; Omalizumab; OVB; QAX576; Reslizumab; Sirolimus; Topical steroid

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; EOTAXIN 3; FLUTICASONE; FLUTICASONE PROPIONATE; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 5 ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LOSARTAN; MEPOLIZUMAB; MERCAPTOPURINE; MONTELUKAST; OC 000459; OMALIZUMAB; PLACEBO; PROSTAGLANDIN D2; PROTON PUMP INHIBITOR; QAX 576; RAPAMYCIN; RESLIZUMAB; RPC 4046; STEROID; SUCRALOSE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ASTHMA; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DYSPHAGIA; ELEMENTAL DIET; ENTERITIS; EOSINOPHILIC ESOPHAGITIS; ESOPHAGUS CANDIDIASIS; FOOD; HUMAN; IMMUNOTHERAPY; INFLAMMATION; LOW DRUG DOSE; MAST CELL; NAUSEA; PALATABILITY; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SENSITIZATION; STEROID THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 84883205107     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.829039     Document Type: Review

References (76)

1. Dellon ES, Gonsalves N, Hirano I, et al. ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). Am J Gastroenterol 2013;108(5):679-92
2. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128(1):3-20; e6; quiz 21-2
3. Taft TH, Kern E, Keefer L, et al. Qualitative assessment of patient-reported outcomes in adults with eosinophilic esophagitis. J Clin Gastroenterol 2011;45(9):769-74
4. Hruz P, Straumann A, Bussmann C, et al. Escalating incidence of eosinophilic esophagitis: A 20-year prospective, population-based study in Olten County. Switzerland. J Allergy Clin Immunol 2011;128(6):1349-50; e5
5. Miller SM, Goldstein JL, Gerson LB. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. Am J Gastroenterol 2011;106(8):1439-45
6. Fiorentino R, Liu G, Pariser AR, Mulberg AE. Cross-sector sponsorship of research in eosinophilic esophagitis: A collaborative model for rational drug development in rare diseases. J Allergy Clin Immunol 2012;130(3):613-16
7. Straumann A, Schoepfer AM. Therapeutic concepts in adult and paediatric eosinophilic oesophagitis. Nat Rev Gastroenterol Hepatol 2012;9(12):697-704
8. Lieberman JA, Chehade M. Eosinophilic esophagitis: Diagnosis and management. Immunol Allergy Clin North Am 2012;32(1):67-81
9. Gonsalves N, Yang GY, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012;142(7):1451-9; e1; quiz e14-5
10. Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: A randomized trial in children. Clin Gastroenterol Hepatol 2008;6(2):165-73
11. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131(5):1381-91
12. Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2012;108(3):366-72
13. Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10(7):742-49 e1
14. Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010;55(5):1313-19
15. Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010;139(5):1526-37; 37 e1
16. Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology 2012;143(2):321-4; e1
17. Gupta SK, Collins MH, Lewis JD. Efficacy and safety of oral budesonide suspension (obs) in pediatric subjects with eosinophilic esophagitis (EoE): Results from the double-blind, placebo-controlled PEER Study. Gastroenterology 2011;140(Suppl 1):S179
18. Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139(2):418-29
19. Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011;9(5):400-9 e1
20. Hirano I. Editorial: Should patients with suspected eosinophilic esophagitis undergo a therapeutic trial of proton pump inhibition? Am J Gastroenterol 2013;108(3):373-5
21. Zhang X, Cheng E, Huo X, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One 2012;7(11):e50037
22. Vashi R, Hirano I. Diet therapy for eosinophilic esophagitis: When, why and how. Curr Opin Gastroenterol 2013;29(4):407-15
23. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007;73(10):1657-64
24. Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 2004;309(1):249-58
25. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 2007;47(6):782-9
26. Vermeulen JH, Gyurkovits K, Rauer H, Engelstatter R. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med 2007;101(10):2182-91
27. Bateman ED, Linnhof AE, Homik L, et al. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008;21(2):264-75
28. Belvisi MG, Bundschuh DS, Stoeck M, et al. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther 2005;314(2):568-74
29. Schroeder S, Fleischer DM, Masterson JC, et al. Successful treatment of eosinophilic esophagitis with ciclesonide. J Allergy Clin Immunol 2012;129(5):1419-21
30. Lee JJ, Fried AJ, Hait E, et al. Topical inhaled ciclesonide for treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2012;130(4):1011; author reply 11-2
31. Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000.Available from: Http://clinicaltrials. gov/ct2/show/study/ NCT01386112? term=Aptalis+eosinophilic +esophagitis&rank=2 [Cited 1 June 2013]
32. OBS in Adolescent and Young Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000.Available from: Http://clinicaltrials. gov/ct2/show/NCT01642212?term=Falk +pharma&rank=31 [Cited 1 June 2013]
33. Dilger K, Lopez-Lazaro L, Marx C, et al. Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes. Digestion 2013;87(2):110-17
34. Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004;43(12):803-21
35. Netzer P, Gschossmann JM, Straumann A, et al. Corticosteroid-dependent eosinophilic oesophagitis: Azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol 2007;19(10):865-9
36. Prussin C. Sirolimus for Eosinophil-Associated Gastrointestinal Disorders. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Http://clinicaltrials.gov/ct2/show/ NCT01814059?term=eosinophilic +esophagitis+and+sirolimus&rank=1 [Cited 13 April 2013]
37. Lucendo AJ. Immunopathological mechanisms of eosinophilic oesophagitis. Allergol Immunopathol (Madr) 2008;36(4):215-27
38. Mulder DJ, Justinich CJ. Understanding eosinophilic esophagitis: The cellular and molecular mechanisms of an emerging disease. Mucosal Immunol 2011;4(2):139-47
39. Zhang Z, Sferra TJ, Eroglu Y. T Cell Co-Stimulatory Molecules: A Co-conspirator in the Pathogenesis of Eosinophilic Esophagitis? Dig Dis Sci 2013;58(6):1497-506
40. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129(2):456-63; 63 e1-3
41. Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 2003;125(5):1419-27
42. Abonia JP, Rothenberg ME. Eosinophilic esophagitis: Rapidly advancing insights. Annu Rev Med 2012;63:421-34
43. Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut 2012;61(12):1765-73
44. Cheng E, Souza RF, Spechler SJ. Tissue remodeling in eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol 2012;303(11):G1175-87
45. Sherrill JD, Rothenberg ME. Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies. J Allergy Clin Immunol 2011;128(1):23-32; quiz 33-4
46. Straumann A, Hoesli S, Bussmann C, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013;68(3):375-85
47. Pettipher R, Vinall SL, Xue L, et al. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther 2012;340(2):473-82
48. Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: A randomised, placebo-controlled, double-blind trial. Gut 2010;59(1):21-30
49. Assa'ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011;141(5):1593-604
50. Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000.Available from: Http://clinicaltrials. gov/ct2/show/NCT00635089? term=Eosinophilic+Esophagitis+and +reslizumab& rank=2 [Cited 9 April 2013]
51. Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000.Available from: Http://clinicaltrials. gov/ct2/show/NCT01022970? term=Eosinophilic+esophagitis+IL- 13&rank=2 [Cited 9 Apr 2013]
52. Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology 2009;137(4):1238-49
53. Fang JC, Hilden K, Gleich GJ, et al. A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab. Gastroenterology 2011;140:5
54. Alpan O. Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda, MD; 2000.Available from: Http://clinicaltrials. gov/show/NCT01040598 [Cited 13 April 2013]
55. Straumann A, Bussmann C, Conus S, et al. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 2008;122(2):425-7
56. Lucendo AJ, De Rezende LC, Jimenez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci 2011;56(12):3551-8
57. Attwood SE, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: A novel treatment using Montelukast. Gut 2003;52(2):181-5
58. Stumphy J, Al-Zubeidi D, Guerin L, et al. Observations on use of montelukast in pediatric eosinophilic esophagitis: Insights for the future. Dis Esophagus 2011;24(4):229-34
59. Filik L. Montelukast and maintenance of steroid-induced remission in eosinophilic esophagitis. Dig Dis Sci 2012;57(1):258-9
60. Alexander J. Trial of Montelukast in Eosinophilic Esophagitis. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000.Available from: Http://clinicaltrials. gov/ct2/show/NCT00511316? term=eosinophilic+esophagitis+and +montelukast&rank=1 [Cited 13 April 2013
61. Hogan W. Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000.Available from: Http://clinicaltrials. gov/ct2/show/NCT01702701? term=eosinophilic+esophagitis+and +montelukast&rank=2 [Cited 13 April 2013
62. Page S. A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000.Available from: Http://clinicaltrials. gov/ct2/show/study/NCT01458418? term=eosinophilic+esophagitis+and +montelukast&rank=3 [Cited 13 April 2013
63. Lee RU. Allergy Immunotherapy in the Management of Eosinophilic Esophagitis (AIMEE). ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000.Available from: Http://clinicaltrials. gov/ct2/show/NCT01685034? term=Eosinophilic+esophagitis+and +immunotherapy& rank=1 [Cited 13 Apr 2013
64. Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358(26):2787-95
65. Abonia JP. Testing Effectiveness of Losartan vs Placebo in Patients With EoE With or Without a CTD. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000.Available from: Http://clinicaltrials. gov/ct2/show/NCT01808196? term=eosinophilic+esophagitis+and +losartan&rank=1 [Cited 13 April 2013
66. Hirano I. Therapeutic end points in eosinophilic esophagitis: Is elimination of esophageal eosinophils enough? Clin Gastroenterol Hepatol 2012;10(7):750-2
67. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: Validation of a novel classification and grading system. Gut 2013;62(4):489-95
68. Nicodeme F, Hirano I, Chen J, et al. Esophageal Distensibility as a Measure of Disease Severity in Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2013;Epub ahead of print
69. Abu-Sultaneh SM, Durst P, Maynard V, Elitsur Y. Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis. Dig Dis Sci 2011;56(1):97-102
70. Lee J, Huprich J, Kujath C, et al. Esophageal diameter is decreased in some patients with eosinophilic esophagitis and might increase with topical corticosteroid therapy. Clin Gastroenterol Hepatol 2012;10(5):481-6
71. Pentiuk S, Putnam PE, Collins MH, Rothenberg ME. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009;48(2):152-60
72. Aceves S, Hirano I, Furuta GT, Collins MH. Eosinophilic gastrointestinal diseases-clinically diverse and histopathologically confounding. Semin Immunopathol 2012;34(5):715-31
73. Caldwell JM, Blanchard C, Collins MH, et al. Glucocorticoid-regulated genes in eosinophilic esophagitis: A role for FKBP51. J Allergy Clin Immunol 2010;125(4):879-88; e8
74. Lu TX, Sherrill JD, Wen T, et al. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol 2012;129(4):1064-75; e9
75. Aceves SS, Newbury RO, Chen D, et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy 2010;65(1):109-16
76. Schoepfer AM, Gonsalves N, Bussmann C, et al. Esophageal dilation in eosinophilic esophagitis: Effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol 2010;105(5):1062-70